Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.33 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 2/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9734894 | 0.81 | AKR1B1 (0.35) | SLC6A2SLC6A4HCAR3HCAR2GSK3B | |
| SCHEMBL5460348 | 0.78 | DRD2 (0.42) | DRD2SIGMAR1HCAR3HCAR2OPRM1 | |
| SCHEMBL29087304 | 0.75 | DRD2 (0.33) | DRD2HCAR3HCAR2OPRM1 | |
| SCHEMBL14544430 | 0.69 | DRD2 (0.44) | DRD2SIGMAR1SLC6A2SLC6A4GSK3B | |
| SCHEMBL1401191 | 0.68 | OPRM1 (0.50) | DRD2SIGMAR1SLC6A2SLC6A4OPRM1 | |
| SCHEMBL187716 | 0.67 | DRD2 (1.00) | DRD2SLC6A2SLC6A4TSHROPRM1 | |
| SCHEMBL1513275 | 0.67 | DRD2 (0.55) | DRD2SIGMAR1SLC6A2SLC6A4OPRM1 | |
| SCHEMBL654759 | 0.67 | DRD2 (0.65) | DRD2SLC6A2SLC6A4 | |
| SCHEMBL29892064 | 0.66 | SIGMAR1 (0.51) | SIGMAR1SLC6A2TSHR | |
| SCHEMBL5235159 | 0.66 | SIGMAR1 (0.51) | SIGMAR1SLC6A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1714961-B1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-12-09 | — | — | EP | disclosed |
| US-7994196-B2 | Indazole compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7994196-B2 | Indazole compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7994196-B2 | Indazole compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20070185168-A1 | Piperidine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | disclosed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | disclosed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | disclosed |
| EP-1736474-A1 | PIPERIDINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-12-27 | — | — | EP | disclosed |
| EP-1714961-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2006-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | CYP3A5, CYP3A43, TP53 | DRD2 3805/4885SIGMAR1 3731/4885SLC6A2 913/4885 |
| US-20070185168-A1 | Piperidine derivatives | GRIN2C, GRIN1, GRIN3A | DRD2 96/4885SIGMAR1 134/4885SLC6A2 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.